Impact of the SGLT2-inhibitor empagliflozin on inflammatory biomarkers after acute myocardial infarction – a post-hoc analysis of the EMMY trial

SGTL2-inhibitors are a cornerstone in the treatment of heart failure, but data on patients with acute myocardial infarction (AMI) is limited. The EMMY trial was the first to show a significant reduction in NTp...

Source: Cardiovascular Diabetology - July 5, 2023 Category: Cardiology Authors: Martin Benedikt, Harald Mangge, Faisal Aziz, Pero Curcic, Sabine Pailer, Markus Herrmann, Ewald Kolesnik, Norbert J. Tripolt, Peter N. Pferschy, Markus Wallner, Andreas Zirlik, Harald Sourij and Dirk von Lewinski Tags: Research Source Type: research